₹-7.40
(Market cap
₹8,007 Cr
Recently Viewed
Clear AllMarket cap
₹8,007 Cr
Revenue (TTM)
₹1,432 Cr
P/E Ratio
53.4
P/B Ratio
3.2
Div. Yield
0.1 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹150 Cr
ROE
3.7 %
ROCE
6.9 %
Industry P/E
29.53
EV/EBITDA
21
Debt to Equity
0.2
Book Value
₹127.4
EPS
₹14.5
Face value
1
Shares outstanding
195,581,816
CFO
₹1,083.09 Cr
EBITDA
₹1,837.95 Cr
Net Profit
₹862.24 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Shilpa Medicare
| 27.0 | 16.6 | 52.0 | 19.8 | 47.0 | 14.1 | 5.4 |
|
BSE Healthcare
| 2.6 | 5.0 | 8.0 | 6.4 | 25.0 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Shilpa Medicare
| -21.4 | 154.6 | 18.7 | -48.0 | 19.9 | 59.3 | -28.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Shilpa Medicare
|
407.8 | 8,007.1 | 1,432.0 | 149.0 | 19.1 | 7.9 | 53.4 | 3.2 |
| 2,756.0 | 34,487.2 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34 | 7.5 | |
| 8,465.5 | 21,125.0 | 2,177.5 | 200.9 | 11.3 | 26.5 | 105.2 | 25.4 | |
| 1,732.2 | 13,169.0 | 2,089.5 | 622.0 | 31.3 | 20.4 | 21.5 | 4.0 | |
| 1,327.6 | 18,343.8 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.5 | 5.1 | |
| 2,043.6 | 32,994.8 | 4,193.0 | 753.8 | 22.7 | 20.8 | 43.8 | 8.2 | |
| 4,820.1 | 22,028.0 | 2,482.3 | 853.6 | 33.7 | 18.9 | 25.8 | 5.5 | |
| 5,112.9 | 8,512.5 | 1,348.5 | 293.5 | 28.1 | 50.7 | 29 | 12.2 | |
| 3,469.3 | 7,989.3 | 1,837.4 | 326.7 | 24.7 | 44.5 | 24.5 | 11.8 | |
| 1,052.0 | 9,714.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 19 | 3.3 |
Five companies that suffered a quality dip
4 min read•By Vishal Goyal
Companies falling short of cash
2 min read•By Rajan Gulati
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States,... Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India. Read more
Incorporated
1987
Chairman
Omprakash Inani
Managing Director
Vishnukant Bhutada
Headquarters
Raichur, Karnataka
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Shilpa Medicare Ltd is ₹407.80 (NSE) and ₹408.05 (BSE) as of 28-Apr-2026 IST. Shilpa Medicare Ltd has given a return of 46.97% in the last 3 years.
The P/E ratio of Shilpa Medicare Ltd is 53.37 times as on 28-Apr-2026, a 81 premium to its peers’ median range of 29.53 times.
The P/B ratio of Shilpa Medicare Ltd is 3.21 times as on 28-Apr-2026, a 30 discount to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
82.81
|
2.73
|
|
2024
|
125.64
|
2.21
|
|
2023
|
0.00
|
1.12
|
|
2022
|
56.83
|
1.89
|
|
2021
|
18.42
|
1.84
|
The 52-week high and low of Shilpa Medicare Ltd are Rs 500.00 and Rs 259.50 as of 28-Apr-2026.
Shilpa Medicare Ltd has a market capitalisation of ₹ 8,007 Cr as on 28-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Shilpa Medicare Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.